Lilly's oral Foundayo outperforms oral semaglutide in weight loss and A1C reduction for type 2 diabetes
Executive summary: Indirect treatment comparison shows Lilly's Foundayo 17.2 mg achieved better weight loss and A1C reduction than oral semaglutide 25 mg over 52 weeks. The results position Foundayo as a highly competitive oral alternative in the rapidly expanding diabetes and obesity drug market.
Who is involved: Eli Lilly, patients with type 2 diabetes.
Likely next: Regulatory review and potential market entry/expansion for Foundayo.
Lilly’s oral Foundayo (orforglipron) at 17.2 mg demonstrated greater weight loss and A1C reduction than Novo Nordisk’s oral semaglutide 25 mg in an indirect treatment comparison based on 52‑week data. The analysis reported a 1.5 percentage‑point advantage in weight loss and a 0.3 percentage‑point greater decline in A1C for Foundayo. These results come from pooled phase 3 trials and were presented as a comparative effectiveness assessment rather than a head‑to‑head study. The outcome strengthens Lilly’s foothold in the oral GLP‑1 receptor agonist class, where oral semaglutide has been the sole approved option since 2019. Clinicians may view Foundayo as an alternative for patients who prioritize modestly better glycemic and weight outcomes, potentially influencing prescribing patterns and formulary placement. For investors, the data support Lilly’s narrative of a differentiated oral pipeline and could accelerate discussions with regulators about label expansion or additional dose strengths. In the near term, Lilly is likely to pursue further real‑world evidence studies and engage with payers to secure favorable reimbursement, while competitors may respond with their own comparative data or price adjustments.
What's next — scenarios
Base: Regulatory approval and market expansion (60%)
Foundayo gains significant market share in the oral diabetes segment.
- FDA/EMA approval decisions
- Commercial launch timelines
Upside: Dominance in the oral GLP-1 market (25%)
Lilly displaces current leaders in oral administration for diabetes/obesity.
- Real-world evidence confirming clinical trial efficacy
- Scale-up of manufacturing capacity
Downside: Competitive pricing pressures (15%)
Profit margins are squeezed due to intense competition from Novo Nordisk and others.
- Price capping legislation
- Aggressive discounting from competitors
What to watch
- FDA/EMA regulatory decisions on orforglipron
- Clinical data from upcoming Phase 3 sub-studies
- Market share data in the oral GLP-1 category
Timeline
- — Lilly's Foundayo 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg (PR Newswire)
Analysis — what this means
Sectors affected
- Pharmaceuticals
- Biotechnology
- Diabetes Care
Historical parallels
- Lilly's retatrutide Phase 3 trials (2026)